Clinical trials
Follow clinical development from trial design and recruitment through results.
- Trial phase
- Status
- Readouts
Company intelligence / Profile preview
Curatio Therapeutics
- Ownership
- Private
- Development stage
- Commercial
01
Overview
Curatio Therapeutics' lead asset, LMP01, is a combination therapy for glioblastoma multiforme. In a small group of end-stage patients with aggressive forms of the disease (IDH 1&2 Wild Types and Unmethylated MGMT), LMP01 has shown anecdotal evidence of safety, efficacy, multi-year survival, and good quality of life in a compassionate use setting
- Therapeutic areas
- Oncology
- Modalities
- Combination therapySmall moleculeBiologic
- Industry
- Biotech
Beyond the preview
Go deeper on Curatio Therapeutics.
Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.
Licensing & deals
Explore licensing agreements, acquisitions, and the assets behind each deal.
- Partners
- Deal terms
- Milestones
Funding history
Trace financing activity and the investors behind a company’s development.
- Funding rounds
- Investors
- Capital raised
Competitive landscape
Compare peer pipelines by target, modality, and therapeutic area.
- Peer companies
- Targets
- Pipeline overlap
Technologies & patents
Explore technology platforms and the patent landscape around relevant assets.
- Platforms
- Patents
- Assignees
Research & analysis
Connect company news and source material to the questions you’re investigating.
- Company news
- Sources
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on Curatio Therapeutics.